|
|
Volumn 105 Suppl 2, Issue , 2012, Pages
|
|
Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINOPHENOL DERIVATIVE;
IVACAFTOR;
N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE;
NEW DRUG;
QUINOLONE DERIVATIVE;
SODIUM CHANNEL;
TRANSMEMBRANE CONDUCTANCE REGULATOR;
CYSTIC FIBROSIS;
DRUG EFFECT;
FEMALE;
FORECASTING;
GENE EXPRESSION REGULATION;
GENETIC PREDISPOSITION;
GENETICS;
HUMAN;
ION TRANSPORT;
MALE;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
MUTATION;
NEEDS ASSESSMENT;
PATHOPHYSIOLOGY;
PHASE 2 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
STOP CODON;
AMINOPHENOLS;
CLINICAL TRIALS, PHASE II AS TOPIC;
CODON, TERMINATOR;
CYSTIC FIBROSIS;
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
DRUGS, INVESTIGATIONAL;
FEMALE;
FORECASTING;
GENE EXPRESSION REGULATION;
GENETIC PREDISPOSITION TO DISEASE;
HUMANS;
ION TRANSPORT;
MALE;
MOLECULAR TARGETED THERAPY;
MUTATION;
NEEDS ASSESSMENT;
QUINOLONES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SODIUM CHANNELS;
|
|
EID: 84865278662
PISSN: None
EISSN: 17581095
Source Type: Journal
DOI: 10.1258/jrsm.2012.12s001 Document Type: Review |
|
Times cited : (14)
|
|
References (0)
|
